Transparency notification received from Fortress Investment Group LLC (Article 14 §1 of the Law of 2 May 2007)
December 15, 2021 01:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Presents Updates on shRNA-Based CAR T Programs at the 63rd ASH Annual Meeting and Exposition
December 13, 2021 01:00 ET
|
Celyad Oncology SA
Data continues to support the versatile potential of non-gene edited shRNA technology with updates from the CYAD-02 and CYAD-211 clinical programsManagement to host conference call today December 13th...
Celyad Oncology Announces Closing of $32.5 Million Private Placement with Fortress Investment Group Affiliate
December 08, 2021 16:05 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Dec. 08, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (“Celyad” or the “Company”), a clinical-stage biotechnology company focused on the...
Celyad Oncology Announces $32.5 Million Private Placement with Fortress Investment Group
December 03, 2021 01:30 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD) (“Celyad” or the “Company”), a clinical-stage biotechnology company focused on the...
Celyad Oncology Presents Preclinical Data on Allogeneic CAR T Therapy Program and Highlights KEYNOTE-B79 Clinical Trial Design at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
November 12, 2021 07:00 ET
|
Celyad Oncology SA
Preclinical data support armoring NKG2D CAR T cells with IL-18 to drive improved anti-tumor activity of the product candidateDevelopment continues for second-generation multiplexing shRNA scaffold for...
Celyad Oncology Announces Third Quarter 2021 Financial Results and Recent Business Highlights
November 10, 2021 16:05 ET
|
Celyad Oncology SA
Phase 1b KEYNOTE-B79 trial set to evaluate CYAD-101 followed by KEYTRUDA® in metastatic colorectal cancer (mCRC) patients with microsatellite stable disease on track to begin by year-end...
Celyad Oncology to Present Updates from Allogeneic and Autologous CAR T Programs at 63rd ASH Annual Meeting and Exposition
November 04, 2021 09:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Nov. 04, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology Announces November 2021 Conference Schedule
November 02, 2021 03:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Information on the Total Number of Voting Rights and Shares (Article 15 of the Law of 2 May 2007)
October 29, 2021 16:05 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Oct. 29, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...
Celyad Oncology to Present New Data on Allogeneic CAR T Therapy Program at the Society for Immunotherapy of Cancer Annual Meeting
October 01, 2021 08:00 ET
|
Celyad Oncology SA
MONT-SAINT-GUIBERT, Belgium, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Celyad Oncology SA (Euronext & Nasdaq: CYAD), a clinical-stage biotechnology company focused on the discovery and development of...